直接抗病毒药物时代注射吸毒人群丙型肝炎的抗病毒治疗  

Antiviral treatment for hepatitis C among injecting drug users in the era of direct-acting antiviral agents

作　　者：潘玲 庞琳[1] Pan Ling;Pang Lin(Division of HCV and STI Control,National Center for AIDS/STD Control and Prevention,Chinese Center for Disease Control and Prevention,Beijing 102206,China)

机构地区：[1]中国疾病预防控制中心性病艾滋病预防控制中心,丙型肝炎与性病防治室,北京102206

出　　处：《中华肝脏病杂志》2020年第10期893-896,共4页Chinese Journal of Hepatology

摘　　要：注射吸毒人群(PWID)丙型肝炎病毒感染率高达67%,要实现世界卫生组织2030年消除病毒性肝炎公共卫生威胁的目标,PWID是需要优先关注的人群。尽管丙型肝炎病毒直接抗病毒药物持续病毒学应答可达到95%以上,但是PWID接受治疗仍存在很大的障碍,尤其是在医疗实践中,由于PWID多伴随合并感染、多重基因型感染、低依从性、药物滥用、美沙酮维持治疗、危险行为及再感染等情况,医生常担心这些因素影响疗效而拒绝给PWID提供丙型肝炎治疗。现对不同感染状态及具有特殊行为特征的PWID开展丙型肝炎治疗的情况及效果的有关研究进行综述,结论为在多学科合作下对PWID人群开展的丙型肝炎治疗安全有效并且能保证治疗的依从性。HCV prevalence among people who inject drugs(PWID)is up to 67%.PWID is a population that needs priority attention to achieve the World Health Organization's goal of eliminating viral hepatitis as a public health threat by 2030.Although the SVR of HCV patients treated with direct-acting antiviral drugs(DAAs)can reach over 95%,especially in medical practice,there are still major obstacles to PWID treatment,because PWID is usually accompanied with concurrent infection,multiple-genotype infections,low compliance,substance abuse,methadone maintenance therapy,and risky behavior and re-infection conditions.Therefore,physicians often concern that these factors will affect the treatment efficacy,and refuse to provide hepatitis C treatment in PWID.This article reviews the relevant studies status and effects of hepatitis C treatment in PWID with different infection states and special behavior characteristics,and further highlights that the multidisciplinary cooperation for hepatitis C treatment in PWID is safe and effective,and can ensure treatment compliance.

关 键 词：静脉吸毒者 治疗 丙型肝炎 

分 类 号：R512.63[医药卫生—内科学]